Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-04-15 21:48:12 ET · period of report 2026-04-13 · accession 0001763494-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-04-15 21:48 | 2026-04-13 | TVTX | Dube Eric M | CEO, Dir | A - Grant | $0.00 | +64.0K | 496.9K | +15% | $0 |
| MT | 2026-04-15 21:48 | 2026-04-15 | TVTX | Dube Eric M | CEO, Dir | S - Sale | $41.09 | -64.0K | 432.9K | -13% | -$2.63M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-13 | A | A | 64,000 | $0.00 | 496,886 | D | — | — | (F1) On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS. |
| 2 | Common | Common Stock | 2026-04-15 | S | D | 56,815 | $41.01 | 440,071 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. (F3) The weighted average sale price for the transaction reported was $41.01, and the range of prices were between $40.51 and $41.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2026-04-15 | S | D | 7,165 | $41.75 | 432,906 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. (F4) The weighted average sale price for the transaction reported was $41.75, and the range of prices were between $41.52 and $42.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 4 | Common | Common Stock | 2026-04-15 | S | D | 20 | $42.66 | 432,886 | D | — | — | (F2) This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. |